These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 11091351

  • 1. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer.
    Singh A, Zelefsky MJ, Raben A, Lombardi D, Leibel SA.
    Int J Cancer; 2000 Oct 20; 90(5):275-80. PubMed ID: 11091351
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.
    J Clin Oncol; 1999 Feb 20; 17(2):517-22. PubMed ID: 10080594
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.
    Ellis RJ, Vertocnik A, Sodee B, Zhou H, Kim E, Young B, Fu P, Colussi V, Spirnak JP, Dinchman KH, Resnick MI.
    Brachytherapy; 2003 Feb 20; 2(4):215-22. PubMed ID: 15062129
    [Abstract] [Full Text] [Related]

  • 8. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA, Stock RG, Stone N.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):645-53. PubMed ID: 14529768
    [Abstract] [Full Text] [Related]

  • 9. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K, Blacksburg S, Stone N, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):630-5. PubMed ID: 22099032
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
    Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):814-9. PubMed ID: 18407435
    [Abstract] [Full Text] [Related]

  • 12. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, Butler W.
    Brachytherapy; 2003 Nov 01; 2(2):108-13. PubMed ID: 15062149
    [Abstract] [Full Text] [Related]

  • 13. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 01; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 14. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):386-92. PubMed ID: 19427741
    [Abstract] [Full Text] [Related]

  • 16. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.
    Radiother Oncol; 2012 Aug 01; 104(2):181-6. PubMed ID: 22853851
    [Abstract] [Full Text] [Related]

  • 17. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
    Zelefsky MJ, Kelly WK, Scher HI, Lee H, Smart T, Metz E, Schwartz L, Fuks Z, Leibel SA.
    J Clin Oncol; 2000 May 01; 18(9):1936-41. PubMed ID: 10784635
    [Abstract] [Full Text] [Related]

  • 18. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):600-7. PubMed ID: 21985944
    [Abstract] [Full Text] [Related]

  • 19. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 01; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.